Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

234.34 +2.61 (+1.13%)
Official Closing Price Updated: 7:00 PM EDT, May 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
A Quiet Trim From LEVIN — O-I Glass Faces Bigger Questions ↗
O-I Glass manufactures glass containers for food and beverage makers across the Americas, Europe, and Asia Pacific. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Healthcare Stocks Are on Fire -- Don't Miss These Opportunities ↗
The healthcare sector outperformed the rest of the market over the past week. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
These 3 Dividend Stocks Are as Close to a Sure Thing as Investing Gets ↗
ExxonMobil, Johnson & Johnson, and Coca-Cola are safe stocks to buy and forget. 
Via The Motley Fool
Topics ETFs Energy
Johnson & Johnson (NYSE:JNJ) Screens Well as a Dependable Dividend Aristocrat ↗
Via Chartmill
News headline image
3 Dividend Kings to Buy and Hold for 20 Years ↗
When it comes to reliable dividend payouts, these three companies keep rewarding their long-term shareholders. 
Via The Motley Fool
Topics Retirement
News headline image
Meet the Dividend King With a Higher Credit Rating Than the U.S. Government ↗
It has plenty of other qualities investors should take note of. 
Via The Motley Fool
Topics Economy
News headline image
3 Dividend Stocks Warren Buffett Would Buy in a Market Crash ↗
Get greedy for these blue chip dividend stocks when Wall Street gets fearful. 
Via The Motley Fool
CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research
Via Investor Brand Network
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Next-Generation CNS Drug Delivery
Via Investor Brand Network
Topics Intellectual Property
News headline image
Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter
From Johnson & Johnson
Via Business Wire
News headline image
CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research
From BioMedWire
Via GlobeNewswire
News headline image
Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors. ↗
This may be an excellent deal for those focused on the long game. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
News headline image
Income or Growth: Which Healthcare Stock Fits Your Portfolio Right Now? ↗
It's important to look beyond near-term volatility. 
Via The Motley Fool
Topics Economy Retirement Stocks
News headline image
2 Dividend Stocks That Are No-Brainer Buys in May ↗
Markets are on the rise, but worries about a recession remain elevated as May gets underway. 
Via The Motley Fool
Topics Economy
News headline image
These Market Signals Alarm Me, but I Still See Profit Potential in These 3 Consumer Stocks ↗
Consumer defensive stocks with a solid dividend history could serve investors well regardless of what happens to the market. 
Via The Motley Fool
News headline image
3 Unstoppable Dividend King Stocks to Buy Right Now for Less Than $550 ↗
These companies pay some of the world's most bankable dividends. 
Via The Motley Fool
News headline image
Safer Dividend King to Buy Now: AbbVie or Johnson & Johnson? ↗
They have combined for 118 years of consecutive dividend increases. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Is Johnson & Johnson Still the Ultimate Safe Dividend Stock to Buy? ↗
It's hard to argue against its reliability. 
Via The Motley Fool
News headline image
Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System
From Johnson & Johnson
Via Business Wire
News headline image
Are Wall Street Analysts Bullish on Johnson & Johnson Stock?
Johnson & Johnson has outperformed the broader market over the past year, and Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects. 
Via Barchart.com
Topics ETFs
News headline image
The Best Dividend Stocks to Buy and Hold Forever ↗
These companies are built to last. And their stocks are built for owning over the long term. 
Via The Motley Fool
News headline image
Got $1,000? Which of These Beaten-Down Healthcare Stocks Is Worth Buying? ↗
These longtime market beaters may not have peaked yet. 
Via The Motley Fool
Topics World Trade
News headline image
Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations
From Johnson & Johnson
Via Business Wire
News headline image
Want to Build Real Wealth in Healthcare? These Stocks Are Worth Considering ↗
These companies are leaders in their fields. 
Via The Motley Fool
News headline image
Johnson & Johnson to Participate in the Bernstein’s 42nd Annual Strategic Decisions Conference
From Johnson & Johnson
Via Business Wire
News headline image
Is Bristol Myers Squibb the Best Bargain in Big Pharma? ↗
This pharma stock is cheap for a reason. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Small Cap or Megacap: Which Healthcare Stock Is Right for You? ↗
Healthcare companies with different market caps offer different rewards and challenges. 
Via The Motley Fool
Top gainers and losers in the S&P500 index during Wednesday's after-hours session. ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.